Experimental drugs in randomized controlled trials for long-COVID : what's in the pipeline? A systematic and critical review
INTRODUCTION: Over three years have passed since the emergence of coronavirus disease 2019 (COVID-19), and yet the treatment for long-COVID, a post-COVID-19 syndrome, remains long overdue. Currently, there is no standardized treatment available for long-COVID, primarily due to the lack of funding for post-acute infection syndromes (PAIS). Nevertheless, the past few years have seen a renewed interest in long-COVID research, with billions of dollars allocated for this purpose. As a result, multiple randomized controlled trials (RCTs) have been funded in the quest to find an effective treatment for long-COVID.
AREAS COVERED: This systematic review identified and evaluated the potential of current drug treatments for long-COVID, examining both completed and ongoing RCTs.
EXPERT OPINION: We identified four completed and 22 ongoing RCTs, investigating 22 unique drugs. However, most drugs were deemed to not have high potential for treating long-COVID, according to three pre-specified domains, a testament to the ordeal of treating long-COVID. Given that long-COVID is highly multifaceted with several proposed subtypes, treatments likely need to be tailored accordingly. Currently, rintatolimod appears to have modest to high potential for treating the myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) subtype, LTY-100 and Treamid for pulmonary fibrosis subtype, and metformin for general long-COVID prevention.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Expert opinion on investigational drugs - 32(2023), 7 vom: 26. Juli, Seite 655-667 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yong, Shin Jie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Drug |
|---|
| Anmerkungen: |
Date Completed 02.11.2023 Date Revised 02.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/13543784.2023.2242773 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360347177 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360347177 | ||
| 003 | DE-627 | ||
| 005 | 20231226082825.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/13543784.2023.2242773 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1201.xml |
| 035 | |a (DE-627)NLM360347177 | ||
| 035 | |a (NLM)37534972 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yong, Shin Jie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Experimental drugs in randomized controlled trials for long-COVID |b what's in the pipeline? A systematic and critical review |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.11.2023 | ||
| 500 | |a Date Revised 02.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Over three years have passed since the emergence of coronavirus disease 2019 (COVID-19), and yet the treatment for long-COVID, a post-COVID-19 syndrome, remains long overdue. Currently, there is no standardized treatment available for long-COVID, primarily due to the lack of funding for post-acute infection syndromes (PAIS). Nevertheless, the past few years have seen a renewed interest in long-COVID research, with billions of dollars allocated for this purpose. As a result, multiple randomized controlled trials (RCTs) have been funded in the quest to find an effective treatment for long-COVID | ||
| 520 | |a AREAS COVERED: This systematic review identified and evaluated the potential of current drug treatments for long-COVID, examining both completed and ongoing RCTs | ||
| 520 | |a EXPERT OPINION: We identified four completed and 22 ongoing RCTs, investigating 22 unique drugs. However, most drugs were deemed to not have high potential for treating long-COVID, according to three pre-specified domains, a testament to the ordeal of treating long-COVID. Given that long-COVID is highly multifaceted with several proposed subtypes, treatments likely need to be tailored accordingly. Currently, rintatolimod appears to have modest to high potential for treating the myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) subtype, LTY-100 and Treamid for pulmonary fibrosis subtype, and metformin for general long-COVID prevention | ||
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Long-COVID | |
| 650 | 4 | |a drug | |
| 650 | 4 | |a post-COVID-19 syndrome | |
| 650 | 4 | |a randomized clinical trial | |
| 650 | 4 | |a treatment | |
| 650 | 7 | |a N,N'-bis(2-(1H-imidazol-2-yl)ethyl)pentanediamide |2 NLM | |
| 650 | 7 | |a NPJ3B3A39Y |2 NLM | |
| 650 | 7 | |a Drugs, Investigational |2 NLM | |
| 700 | 1 | |a Halim, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Halim, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Ming, Long Chiau |e verfasserin |4 aut | |
| 700 | 1 | |a Goh, Khang Wen |e verfasserin |4 aut | |
| 700 | 1 | |a Alfaresi, Mubarak |e verfasserin |4 aut | |
| 700 | 1 | |a AlShehail, Bashayer M |e verfasserin |4 aut | |
| 700 | 1 | |a Al Fares, Mona A |e verfasserin |4 aut | |
| 700 | 1 | |a Alissa, Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a Sulaiman, Tarek |e verfasserin |4 aut | |
| 700 | 1 | |a Alsalem, Zainab |e verfasserin |4 aut | |
| 700 | 1 | |a Alwashmi, Ameen S S |e verfasserin |4 aut | |
| 700 | 1 | |a Khamis, Faryal |e verfasserin |4 aut | |
| 700 | 1 | |a Al Kaabi, Nawal A |e verfasserin |4 aut | |
| 700 | 1 | |a Albayat, Hawra |e verfasserin |4 aut | |
| 700 | 1 | |a Alsheheri, Ahmed |e verfasserin |4 aut | |
| 700 | 1 | |a Garout, Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a Alsalman, Jameela |e verfasserin |4 aut | |
| 700 | 1 | |a Alfaraj, Amal H |e verfasserin |4 aut | |
| 700 | 1 | |a Alhajri, Mashael |e verfasserin |4 aut | |
| 700 | 1 | |a Dhama, Kuldeep |e verfasserin |4 aut | |
| 700 | 1 | |a Alburaiky, Lamees M |e verfasserin |4 aut | |
| 700 | 1 | |a Alsanad, Ahlam H |e verfasserin |4 aut | |
| 700 | 1 | |a AlShurbaji, Abdelmunim T |e verfasserin |4 aut | |
| 700 | 1 | |a Rabaan, Ali A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on investigational drugs |d 1995 |g 32(2023), 7 vom: 26. Juli, Seite 655-667 |w (DE-627)NLM093775326 |x 1744-7658 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2023 |g number:7 |g day:26 |g month:07 |g pages:655-667 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/13543784.2023.2242773 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2023 |e 7 |b 26 |c 07 |h 655-667 | ||